CIDARA THERAPEUTICS INC

NASDAQ: CDTX (Cidara Therapeutics, Inc.)

Kemas kini terakhir: 14 jam lalu

24.28

-1.42 (-5.53%)

Penutupan Terdahulu 25.70
Buka 25.85
Jumlah Dagangan 162,511
Purata Dagangan (3B) 154,407
Modal Pasaran 314,906,752
Harga / Pendapatan (P/E Ke hadapan) 5.75
Harga / Jualan (P/S) 99.60
Harga / Buku (P/B) 1.34
Julat 52 Minggu
10.14 (-58%) — 28.42 (17%)
Tarikh Pendapatan 11 Aug 2025 - 15 Aug 2025
Margin Operasi (TTM) -7,154.43%
EPS Cair (TTM) -26.82
Pertumbuhan Hasil Suku Tahunan (YOY) -100.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 2.19%
Nisbah Semasa (MRQ) 4.25
Aliran Tunai Operasi (OCF TTM) -176.53 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -67.09 M
Pulangan Atas Aset (ROA TTM) -40.46%
Pulangan Atas Ekuiti (ROE TTM) -219.59%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Cidara Therapeutics, Inc. Menaik Menaik

AISkor Stockmoo

0.9
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga -4.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 4.0
Purata 0.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CDTX 315 M - - 1.34
VRNA 6 B - - 27.21
CRNX 3 B - - 2.12
VRDN 1 B - - 2.44
NVAX 1 B - 2.45 -
ZYME 866 M - - 2.67

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak® platform targeting oncologic, viral and autoimmune diseases.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 1.38%
% Dimiliki oleh Institusi 69.49%

Pemilikan

Nama Tarikh Syer Dipegang
Acuta Capital Partners, Llc 31 Mar 2025 125,708
195.55195.55148.90148.90102.25102.2555.6055.608.958.95Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
10.14 (-58%) — 28.42 (17%)
Julat Harga Sasaran
35.00 (44%) — 50.00 (105%)
Tinggi 50.00 (Guggenheim, 105.93%) Beli
Median 40.50 (66.80%)
Rendah 35.00 (RBC Capital, 44.15%) Beli
35.00 (Needham, 44.15%) Beli
35.00 (HC Wainwright & Co., 44.15%) Beli
Purata 41.33 (70.22%)
Jumlah 6 Beli
Harga Purata @ Panggilan 23.01
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Needham 23 May 2025 35.00 (44.15%) Beli 24.28
10 Apr 2025 35.00 (44.15%) Beli 17.09
RBC Capital 23 May 2025 35.00 (44.15%) Beli 24.28
Guggenheim 16 May 2025 50.00 (105.93%) Beli 25.50
09 May 2025 35.00 (44.15%) Beli 18.63
JMP Securities 09 May 2025 47.00 (93.57%) Beli 18.63
29 Apr 2025 46.00 (89.46%) Beli 21.12
Citizens Capital Markets 12 Mar 2025 46.00 (89.46%) Beli 23.00
HC Wainwright & Co. 10 Mar 2025 35.00 (44.15%) Beli 22.39

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
15 May 2025 Pengumuman Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
13 May 2025 Pengumuman Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
08 May 2025 Pengumuman Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
01 May 2025 Pengumuman Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
30 Apr 2025 Pengumuman Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
24 Apr 2025 Pengumuman Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
01 Apr 2025 Pengumuman Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
01 Apr 2025 Pengumuman Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
19 Mar 2025 Pengumuman Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
18 Mar 2025 Pengumuman Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
17 Mar 2025 Pengumuman Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
06 Mar 2025 Pengumuman Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Papar semua
28.5128.5125.0225.0221.5321.5318.0318.0314.5414.54May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
1.5001.5001.0001.0000.5000.5000.0000.000-0.500-0.500MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda